Perioperative immunotherapy in muscle-invasive bladder cancer and upper tract urothelial carcinoma Journal Article

Authors: Teo, M. Y.; Rosenberg, J. E.
Article Title: Perioperative immunotherapy in muscle-invasive bladder cancer and upper tract urothelial carcinoma
Abstract: Neoadjuvant chemotherapy improves survival in patients with muscle-invasive bladder cancer. However, a significant proportion of patients are ineligible for cisplatin owing to renal impairment or other medical comorbidities. The introduction of anti-programmed cell death protein 1/programmed death-ligand 1(PD1/PD-L1) checkpoint inhibitors has redefined the therapeutic landscape for platinum-resistant urothelial cancers; their clinical efficacy and favorable toxicity render these agents attractive therapeutic options either as monotherapy or in combination with other agents in earlier disease states, including muscle-invasive disease. We review potential perioperative immunotherapy strategies, ongoing clinical trials and areas of unmet needs, including upper tract disease and non-urothelial cancers. © 2018 Elsevier Inc.
Keywords: cancer chemotherapy; overall survival; review; cisplatin; placebo; drug efficacy; drug safety; multimodality cancer therapy; gemcitabine; paclitaxel; combined modality therapy; neoadjuvant therapy; ipilimumab; cancer immunotherapy; pathology; bladder tumor; urinary bladder neoplasms; kidney neoplasms; docetaxel; immunology; immunotherapy; kidney tumor; drug response; urothelial carcinoma; ureteral neoplasms; neoadjuvant chemotherapy; platinum complex; taxane derivative; carcinoma, transitional cell; transitional cell carcinoma; pemetrexed; urinary tract; ureter tumor; vinflunine; programmed death 1 ligand 1; randomized controlled trial (topic); phase 2 clinical trial (topic); phase 3 clinical trial (topic); pd-l1; muscle invasive bladder cancer; muscle-invasive bladder cancer; nivolumab; humans; human; priority journal; pembrolizumab; antagonists and inhibitors; atezolizumab; immunological antineoplastic agent; antineoplastic agents, immunological; pd1; renal pelvis urothelial carcinoma; ureteral carcinoma; b7-h1 antigen
Journal Title: Urologic Clinics of North America
Volume: 45
Issue: 2
ISSN: 0094-0143
Publisher: W.B. Saunders Co-Elsevier Inc.  
Date Published: 2018-05-01
Start Page: 287
End Page: 295
Language: English
DOI: 10.1016/j.ucl.2017.12.011
PUBMED: 29650143
PROVIDER: scopus
Notes: Review -- Export Date: 1 May 2018 -- Source: Scopus
Altmetric Score
MSK Authors
  1. Jonathan Eric Rosenberg
    240 Rosenberg
  2. Min Yuen   Teo
    30 Teo